REGENXBIO Inc. (RGNX) Sets 52-Week High

June 26, 2018 - By Ronnie Lemelle

REGENXBIO Inc. (NASDAQ:RGNX) Corporate Logo

The company REGENXBIO Inc. (NASDAQ:RGNX) hit yearly high with $76.48 target or 6.00 % above today’s $72.15 stock price. The yearly high was announced on Jun, 26 by Barchart.com. It has $2.30 billion market cap. At $76.48 target, the company’s valuation could be $138.24 million more.

Ticker’s shares touched $72.15 during the last trading session after 1.33% change.Currently REGENXBIO Inc. is uptrending after 165.15% change in last June 26, 2017. RGNX has 137,111 shares volume. The stock outperformed the S&P 500 by 152.58%.

REGENXBIO Inc. (NASDAQ:RGNX) is anticipated to announce earnings on August, 14., as reported by Faxor. Analysts predict $1.90 earnings per share. That’s $2.37 up or 504.26 % from 2017’s earnings of $-0.47. If the current earnings per share of $1.90 is accurate, RGNX’s profit could hit $60.67M. Analysts at Wall Street see REGENXBIO Inc.’s -36.67 % negative EPS growth compared to $3.00 earnings per share for previous quarter.

More recent REGENXBIO Inc. (NASDAQ:RGNX) news were posted by Globenewswire.com, Benzinga.com and Benzinga.com. The first one has “Factors of Influence in 2018, Key Indicators and Opportunity within Immune Pharmaceuticals, Wells Fargo, Anadarko …” as a title and was posted on June 25, 2018. The next is “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018. And last was posted on June 21, 2018, called “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street”.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease.The company has $2.30 billion market cap. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.The P/E ratio is 43.33. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

REGENXBIO Inc. (NASDAQ:RGNX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.